Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERMEDIATE-GRADE LYMPHOMAS TREATED WITH AMIDE-DOXORUBICIN-VINCRISTINE-PREDNISONE-BLEOMYCIN ALTERNATED WITH LOPHOSPHAMIDE-METHOTREXATE-ETOPOSIDE-DEXAMETHASONE - APPLICATION OF PROGNOSTIC MODELS TO DATA-ANALYSIS
Autore:
VELASQUEZ WS; MCLAUGHLIN P; FULLER LM; ALLEN PK; TUCKER SL; SWAN F; RODRIGUEZ MA; HAGEMEISTER FB; CABANILLAS FF;
Indirizzi:
ST LOUIS UNIV,MED CTR,DIV BONE MARROW TRANSPLANTAT ONCOL & HEMATOL,3635 VISTA AVE,POB 15250 ST LOUIS MO 63110 UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL HOUSTON TX 00000 UNIV TEXAS,MD ANDERSON CANC CTR,DEPT RADIOTHERAPY HOUSTON TX 00000 UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH HOUSTON TX 77030
Titolo Testata:
Cancer
fascicolo: 9, volume: 73, anno: 1994,
pagine: 2408 - 2416
SICI:
0008-543X(1994)73:9<2408:ILTWA>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
LARGE-CELL LYMPHOMA; SOUTHWEST-ONCOLOGY-GROUP; NON-HODGKINS-LYMPHOMA; COMBINATION CHEMOTHERAPY; MACOP-B; MALIGNANT-LYMPHOMAS; AGGRESSIVE LYMPHOMA; PROMACE-CYTABOM; DIFFUSE; TRIAL;
Keywords:
AMIDE-DOXORUBICIN-VINCRISTINE-PREDNISONE-BLEOMYCIN; LOPHOSPHAMIDE-METHOTREXATE-ETOPOSIDE-DEXAMETHASONE; INTERMEDIATE-GRADE LYMPHOMAS; PROGNOSTIC MODELS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
W.S. Velasquez et al., "INTERMEDIATE-GRADE LYMPHOMAS TREATED WITH AMIDE-DOXORUBICIN-VINCRISTINE-PREDNISONE-BLEOMYCIN ALTERNATED WITH LOPHOSPHAMIDE-METHOTREXATE-ETOPOSIDE-DEXAMETHASONE - APPLICATION OF PROGNOSTIC MODELS TO DATA-ANALYSIS", Cancer, 73(9), 1994, pp. 2408-2416

Abstract

Background. Numerous treatment strategies have been tried with the aim of improving results for patients with intermediate-grade lymphomas (IGL) over those achieved with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo), and numerous prognostic models have been developed to identify and separate risk groups. This study reports on a new protocol for Ann Arbor Stages II-IV IGL that consists of CHOP-Bleo alternated with a new regimen of cyclophosphamide, methotrexate, etoposide, and dexamethasone (CMED) and radiation therapyand demonstrates the usefulness of prognostic models for identifying risk groups and comparing treatment programs. Methods. One hundred seventy patients with Ann Arbor Stages II-IV IGL were treated with alternating cycles of CHOP-Blee and CMED for a total of 12 cycles. Involved field radiation therapy was interspersed with courses of chemotherapy for patients with Stage II and Stage III disease. Results were analyzed and compared with those of the authors' previous study of CHOP-Bleo and radiation therapy using the Ann Arbor staging system, their earlier prognostic model, and the recently published International Index. Results. A complete remission occurred in 78% of the patients. The overall 5-year survival rate was 67%. Survival was better for patients withAnn Arbor Stage II disease (80%) than for those with Stage III or Stage IV (67% and 58%, respectively). High tumor burden, above-normal levels of serum lactic dehydrogenase, serum PB-microglobulin, and Ann Arbor Stage IV disease were adverse factors. The International Index and the authors' earlier prognostic model separated four prognostic groups. CHOP-Bleo/CMED was generally well tolerated. Neutropenic fever was the major complication that occurred in 25 patients during treatment. Six of these patients died of sepsis. Conclusions. This study demonstrated that CHOP-Bleo/CMED is a well-tolerated regimen that produced better results than those reported for a former study that used CHOP-Bleo alone. Further, results for CHOP-Bleo/CMED compared favorably with those of other second- and third-generation regimens. The study also validated the usefulness of prognostic models and, in particular, the new International Index for identifying risk groups.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 21:56:09